deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03164772

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC)

Sponsor: Boehringer Ingelheim

Conditions Metastatic Non-small Cell Lung Cancer NSCLC
Interventions BI 1361849 Durvalumab PharmaJet Tropis® device Tremelimumab
Updated 19 times since 2017 Last updated: Oct 3, 2022 Started: Dec 20, 2017 Primary completion: Oct 29, 2021 Completion: Oct 29, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Metastatic Non-small Cell Lung Cancer and NSCLC and is currently completed. Boehringer Ingelheim leads this study, which shows 19 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2017 – ~Feb 2018 · 8 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Dec 2021 · 9 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – present · 17 months · monthly snapshot

Change History

19 versions recorded

  1. Feb 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Nov 2022 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 14 earlier versions

  1. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE1_PHASE2

  2. Dec 2021 — Sep 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  3. Mar 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  7. Apr 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  8. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Aug 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  10. Mar 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  13. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  14. Jun 2017 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
  • Cancer Research Institute, New York City
  • CureVac
  • Ludwig Institute for Cancer Research
  • MedImmune LLC
  • PharmaJet, Inc.
Data source: Ludwig Institute for Cancer Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations